Propensity-score matched analysis of the pathologic outcomes and survival benefits of neoadjuvant therapy in stage II-III anal adenocarcinoma.
Sameh Hany EmileNir HoreshZoe GaroufaliaRachel GefenPeige ZhouSteven D WexnerPublished in: Journal of surgical oncology (2023)
Neoadjuvant therapy before APR was associated with significant downstaging of anal adenocarcinomas and lower 90-day mortality, yet similar OS to patients who were surgically treated without neoadjuvant treatment.